Day: September 18, 2020

SalMar ASA sitt datterselskap Arnarlax AS, som gjennom sitt datterselskap Arnarlax Ehf driver med oppdrettsvirksomhet på Island, har engasjert DNB Markets som tilrettelegger i forbindelse med en mulig rettet emisjon, samt notering av selskapets aksjer på Merkur Market i løpet av 2020.SalMar vurderer ikke nedsalg i forbindelse med transaksjonen og vil opprettholde en eierandel på over 50% i Arnarlax etter transaksjonen.For ytterligere informasjon henvises det til melding sendt ut av Arnarlax som man kan finne på www.arnarlax.isDenne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12.

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus.The test  targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.1Using the Elecsys Anti-SARS-COV-2 S antibody test, together with the Elecsys Anti-SARS-CoV-2* test launched in May, can help to more effectively determine the percentage of a population who already have antibodies against SARS-COV-2.Basel, 18 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA).Launching COVID-19 diagnostic tests for active...

                                                                                                                                                            Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate FoundationPARIS – September 18, 2020 – Sanofi today announced the appointment of Dr. Jean-Christophe Rufin as President of the Sanofi Espoir Corporate Foundation. Jean-Christophe Rufin succeeds Xavier Darcos, who presided over the Foundation since 2015.“We are delighted that Dr. Jean-Christophe Rufin has accepted to serve as  President of the Sanofi Espoir Foundation”, said Serge Weinberg, President of Sanofi. “His experience as both a physician and diplomat gives him a broad expertise in humanitarian and public health issues around the world. He will enable us to step up our response...

 Le Dr Jean-Christophe Rufin est nommé Présidentde la Fondation d’entreprise Sanofi EspoirParis (France) – Le 18 septembre 2020 – Sanofi annonce la nomination du Dr Jean-Christophe Rufin à la présidence de la Fondation d’entreprise Sanofi Espoir. Jean-Christophe Rufin succède à Xavier Darcos, qui présidait la Fondation depuis 2015.« Nous sommes très heureux que le Dr Jean-Christophe Rufin ait accepté de présider la Fondation Sanofi Espoir », déclare Serge Weinberg, Président de Sanofi. « Son expérience de médecin et de diplomate en fait un grand connaisseur des questions humanitaires et de santé publique dans le monde. Il nous permettra de renforcer notre réponse face à la détresse sanitaire des populations vulnérables. Par son œuvre littéraire, il a fait largement la preuve de son engagement humaniste et de sa qualité d’observateur des...

 Saint-Herblain (France), September 18, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the retirement of its Chief Financial Officer, David Lawrence, at the end of 2020.The Company has initiated a search process with a leading global recruitment agency to identify a new CFO, aiming for an on-boarding in the first quarter of 2021.Until the end of the year, David will manage a handover process to ensure a smooth transition with Manfred Tiefenbacher, VP Finance, who will assume responsibility for all operational finance matters.In addition, David has agreed to continue to support Valneva’s CEO in an advisory capacity in the early part of 2021.Thomas Lingelbach, Chief Executive Officer of Valneva, said, “We would like to thank David for his great contributions...

 Saint-Herblain (France), 18 septembre 2020 – Valneva SE (“Valneva” ou le Groupe), société spécialisée dans les vaccins contre des maladies générant d’importants besoins médicaux, a annoncé aujourd’hui le départ à la retraite de son directeur financier David Lawrence à la fin de l’année 2020.Valneva a lancé un processus de recrutement d’un nouveau directeur financier auprès d’une agence de recrutement internationale avec pour objectif l’arrivée d’un nouveau directeur financier au premier trimestre 2021.Jusqu’à la fin de l’année, afin d’assurer une transition en douceur, David Lawrence assurera un processus de transfert de responsabilités à Manfred Tiefenbacher, VP Finance, qui sera responsable de toutes les activités financières opérationnelles.David Lawrence a de plus accepté de continuer à conseiller le CEO de Valneva au début...

ROTTERDAM, The Netherlands (18 September 2020, 07:00 CET) – IMCD N.V. (“IMCD” or the “Company”), a leading distributor of speciality chemicals and ingredients, today announces that it has acquired 100% of the share capital of Oy Kokko-Fiber Ab (“Kokko-Fiber”), a leading supplier of fiber-reinforced plastic composite materials in Finland.Kokko-Fiber, founded in 1994, serves a broad customer base that includes many of the largest Finnish companies that use fiber-reinforced plastics in their operations. The company has five employees and generated a revenue of €9.0 million in 2019.Attached, please find the release in pdf format.– xxx –About IMCD N.V. IMCD is a market leader in the sales, marketing and distribution of speciality chemicals and food ingredients. Its result-driven professionals provide market-focused solutions to...

EMPACTA is the first global phase III trial to show efficacy with Actemra/RoActemra in COVID-19 associated pneumonia and the first with a focus on enrolling largely underserved and minority patientsThere was no statistical difference in mortality between patients who received Actemra/RoActemra or placeboRoche plans to share these results with health authorities, including the US FDABasel, 18 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97])....

 COMPASS Pathways announces pricing of upsized initial public offeringLondon, UK – September 18, 2020COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its upsized initial public offering in the United States of 7,500,000 American Depositary Shares (“ADSs”) representing 7,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of $127.5 million. All ADSs sold in the offering were offered by COMPASS. The ADSs are expected to begin trading on the Nasdaq Global Select Market on September 18, 2020 under the ticker symbol “CMPS.” The offering is expected to close on or about September 22, 2020, subject to the satisfaction of customary closing conditions....

Attached is information regarding a transaction between a primary insider and a  financially connected party.  Attachments201809 Bogi Nils – Sala201809 Möskvi – Kaup